DiaMedica shareholders approve 2M share increase in 2019 omnibus incentive plan and new director compensation cap

DiaMedica Therapeutics Inc.

Shareholders approved amendment to 2019 Omnibus Incentive Plan, increasing authorized shares by 2,000,000.
The amended plan imposes a dollar limit on non-employee director compensation per calendar year.
All six director nominees were elected; Richard Pilnik received 3.4M for, 1.3M withheld.
Baker Tilly US, LLP appointed as independent registered public accounting firm for 2022.
The plan became effective May 18, 2022 and expires on May 21, 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.